Dose adjusted EPOCH-R is superior to RCHOP in frontline treatment of mediastinal large B cell lymphoma
DA-EPOCH-R improves CMR, PFS, and OS compared to R-CHOP-21 with radiotherapy in PMLBCL, particularly in high-risk patients. Longer follow-up is needed to assess long-term toxicities.
Authors
- Kamal Hosni Al-Rabi (ORCID: https://orcid.org/0009-0007-7492-6374)
- Mohammad Al-Rwashdeh
- Hikmat Abdel‐Razeq (ORCID: https://orcid.org/0000-0003-2833-6051)
- Omar Shahin
- Khalid Halahleh (ORCID: https://orcid.org/0000-0002-1161-9138)
- Akram Al‐Ibraheem (ORCID: https://orcid.org/0000-0002-0978-4716)
- Mohammad Ma’koseh
- Heba Farfoura
- Zaid Abdel Rahman (ORCID: https://orcid.org/0000-0003-2959-1177)
- Abeer Yaseen
- Alaa Abufara
- Nebras Abu Abed
- Ro’a Muqbel
Institutions
- University of Jordan (JO)
- King Hussein Cancer Center (JO)
Publication Details
- Journal
- Hematology
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1080/16078454.2025.2515337
- Citations
- 2
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.94